



# TORRENT PHARMACEUTICALS LIMITED

Regd. Office : Torrent House, Off Ashram Road, Ahmedabad-380 009

## UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE 2010

[Rs. in Lacs except per share data]

PARTICULARS	UNAUDITED		AUDITED
	QUARTER ENDED		YEAR ENDED
	30-Jun-10	30-Jun-09	31-Mar-10
Sales (see note 3)	53488	47368	186730
Less : Excise and similar duties collected	946	785	3437
<b>Net Sales</b>	<b>52542</b>	<b>46583</b>	<b>183293</b>
Other Operating Income	1558	1522	8311
<b>Total Income</b>	<b>54100</b>	<b>48105</b>	<b>191604</b>
<b>Expenditure</b>			
(Increase) / Decrease in Stock in Trade and Work in Progress	(4263)	(1852)	(2136)
Consumption of Raw / Packing Material	14404	11470	41064
Purchase of Traded Goods	6263	5397	18169
Employees Cost	9225	7404	31616
Research and Development Expenses	3149	3719	12022
Depreciation and Amortization	1421	1127	6609
Other Expenditure	14110	12337	48791
<b>Total Expenditure</b>	<b>44309</b>	<b>39602</b>	<b>156135</b>
<b>Profit from Operations before Other Income and Interest</b>	<b>9791</b>	<b>8503</b>	<b>35469</b>
Other Income	223	213	904
<b>Profit before Interest</b>	<b>10014</b>	<b>8716</b>	<b>36373</b>
Net Borrowing Costs	244	298	1651
<b>Profit from Ordinary Activities before tax</b>	<b>9770</b>	<b>8418</b>	<b>34722</b>
Tax Expense (see note 4)	2348	6906	11602
<b>Net Profit from Ordinary Activities after tax</b>	<b>7422</b>	<b>1512</b>	<b>23120</b>
Paid-up Equity Share Capital (Face Value of Rs.5)	4231	4231	4231
Reserves excluding Revaluation Reserves	-	-	78867
Basic and Diluted EPS for the period	8.77	1.79	27.32
Public shareholding			
Number of shares	24109500	24109500	24109500
Percentage of shareholding	28.49%	28.49%	28.49%
Promoters and promoter group Shareholding			
(a) Pledged/Encumbered			
- Number of shares	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil
- Percentage of shares (as a% of the total share capital of the company)	Nil	Nil	Nil
(b) Non-encumbered			
- Number of shares	60501860	60501860	60501860
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%
- Percentage of shares (as a% of the total share capital of the company)	71.51%	71.51%	71.51%

### Notes :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 30-Jul-10. The statutory auditors have carried out a limited review of the results for the quarter ended 30-Jun-10. There is no adverse observation in the limited review report on this statement of financial results.
- a) The statement of financial results consolidate the financial results of fourteen wholly owned subsidiaries with that of the Company.  
b) "Torrent Pharma (UK) Limited", a wholly owned subsidiary, was incorporated in United Kingdom on 11-May-10.
- The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Rs. in lacs

PARTICULARS	UNAUDITED			AUDITED
	Quarter Ended			Year Ended
	30-Jun-10	30-Jun-09	Growth %	31-Mar-10
<b>(A) Sales in India</b>				
Branded Business	22459	19865	13%	72913
Contract Manufacture	4407	5002	(12%)	18970
Others	132	30	-	178
<b>Total Sales in India</b>	<b>26998</b>	<b>24897</b>	<b>8%</b>	<b>92061</b>
<b>(B) Sales outside India</b>	<b>26490</b>	<b>22471</b>	<b>18%</b>	<b>94669</b>
<b>Total Sales (A+B)</b>	<b>53488</b>	<b>47368</b>	<b>13%</b>	<b>186730</b>
Less : Excise and similar duties	946	785	-	3437
<b>Net Sales</b>	<b>52542</b>	<b>46583</b>	<b>13%</b>	<b>183293</b>

- During the comparative quarter, "MAT credit entitlement asset" of Rs 5286 lacs recognised in earlier years, was written-off.
- During the quarter, two investor complaints were received and resolved. No complaints were pending either at the beginning or at the end of the quarter.
- The figures for the comparative periods have been regrouped, wherever necessary, to make them comparable with the figures for the current periods.
- Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

Rs. in lacs

PARTICULARS	Quarter Ended		Year Ended
	30-Jun-10	30-Jun-09	31-Mar-10
Net Sales & Operating Income	41838	36062	144895
Profit before tax	10402	8778	31372
Profit after tax	8313	1913	20737

- The standalone audited financial results for the quarter ended are available on the Company's website at [www.torrentpharma.com](http://www.torrentpharma.com).

For **TORRENT PHARMACEUTICALS LIMITED**

sd/-

Place : Ahmedabad

Date : 30-Jul-10

**SUDHIR MEHTA**

Chairman